PD
TBPH icon

Point72 (DIFC)’s Theravance Biopharma TBPH Stock Holding History

Point72 (DIFC)’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,839
Closed -$25.4K – 2076
2025
Q1 		$25.4K Buy
+2,839
New +$26.4K ﹤0.01% 1319
2024
Q3 		– Sell
-1,824
Closed -$15.5K – 1813
2024
Q2 		$15.5K Buy
+1,824
New +$16.5K ﹤0.01% 1274

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 (DIFC)'s TBPH Position: Q2 2025 in Review

Point72 (DIFC) sold out of Theravance Biopharma (TBPH) in Q2 2025, closing a stake of 2,839 shares — an estimated $25.4K sold.

Point72 (DIFC) first reported a position in TBPH in Q2 2024 and held it in 2 quarters. The position peaked at $25.4K in Q1 2025. 135 funds tracked by Wall St. Rank hold TBPH as of Q2 2025.

  • Point72 (DIFC) reported no remaining Theravance Biopharma position as of Q2 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 2,839 Theravance Biopharma shares in Q2 2025, an estimated $25.4K.
  • Point72 (DIFC) first reported a position in Theravance Biopharma in Q2 2024 and held it in 2 quarters.
  • Point72 (DIFC)'s Theravance Biopharma position peaked at $25.4K in Q1 2025.
  • 135 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2025.

Based on Point72 (DIFC)'s 13F filing for Q2 2025, filed 14 Aug 2025.